1. Preface
1.1. Report Description
1.1.1. Purpose of the Report
1.1.2. Target Audience
1.1.3. Key Offerings
1.2. Market Segmentation
1.3. Research Methodology
1.3.1. Phase I - Secondary Research
1.3.2. Phase II - Primary Research
1.3.3. Phase III - Expert Panel Review
1.3.4. Assumptions
1.3.5. Approach Adopted

2. Executive Summary
2.1. Market Snapshot: Global Neuroendocrine Tumor Treatment Market
2.2. Global Neuroendocrine Tumor Treatment Market, By Drug, 2023 (US$ Million)
2.3. Global Neuroendocrine Tumor Treatment Market, By Geography, 2023 (US$ Million)
2.4. Attractive Investment Proposition by Geography, 2023

3. Neuroendocrine Tumor Treatment Market: Competitive Analysis
3.1. Market Positioning of Key Neuroendocrine Tumor Treatment Market Vendors
3.2. Strategies Adopted by Neuroendocrine Tumor Treatment Market Vendors
3.3. Key Industry Strategies
3.4. Tier Analysis 2023 Versus 2032

4. Neuroendocrine Tumor Treatment Market: Macro Analysis & Market Dynamics
4.1. Introduction
4.2. Global Neuroendocrine Tumor Treatment Market Value, 2022 - 2032, (US$ Million)
4.3. Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Key Challenges
4.3.4. Key Opportunities
4.4. Impact Analysis of Drivers and Restraints
4.5. See-Saw Analysis
4.6. Porter's Five Force Model
4.6.1. Supplier Power
4.6.2. Buyer Power
4.6.3. Threat Of Substitutes
4.6.4. Threat Of New Entrants
4.6.5. Competitive Rivalry
4.7. PESTEL Analysis
4.7.1. Political Landscape
4.7.2. Economic Landscape
4.7.3. Technology Landscape
4.7.4. Legal Landscape
4.7.5. Social Landscape

5. Neuroendocrine Tumor Treatment Market: By Drug, 2022-2032, USD (Million)
5.1. Market Overview
5.2. Growth & Revenue Analysis: 2023 Versus 2032
5.3. Market Segmentation
5.3.1. mTOR protein inhibitors (Everolimus)
5.3.2. Tyrosine kinase 3 inhibitors (Sunitinib)
5.3.3. Somatostatin receptor antagonists (Lu-Dotatate)
5.3.4. Growth hormone releasing factor antagonists (Lanreotide)
5.3.5. Somatostatin receptor agonists (Octreotide)
5.3.6. Pipeline Analysis
5.3.6.1. Phase III Drugs
5.3.6.1.1. Vandetanib
5.3.6.1.2. Fotemustine and Ipilimumab
5.3.6.1.3. 177Lu-edotreotide PRRT
5.3.6.1.4. Sulfatinib
5.3.6.2. Tabular Representation of Phase II and I Drugs


6. North America Neuroendocrine Tumor Treatment Market, 2022-2032, USD (Million)
6.1. Market Overview
6.2. Neuroendocrine Tumor Treatment Market: By Drug, 2022-2032, USD (Million)
6.3.Neuroendocrine Tumor Treatment Market: By Region, 2022-2032, USD (Million)
6.3.1.North America
6.3.1.1. U.S.
6.3.1.1.1. Neuroendocrine Tumor Treatment Market: By Drug, 2022-2032, USD (Million)
6.3.1.2. Canada
6.3.1.2.1. Neuroendocrine Tumor Treatment Market: By Drug, 2022-2032, USD (Million)
6.3.1.3. Rest of North America
6.3.1.3.1. Neuroendocrine Tumor Treatment Market: By Drug, 2022-2032, USD (Million)

7. UK and European Union Neuroendocrine Tumor Treatment Market, 2022-2032, USD (Million)
7.1. Market Overview
7.2. Neuroendocrine Tumor Treatment Market: By Drug, 2022-2032, USD (Million)
7.3.Neuroendocrine Tumor Treatment Market: By Region, 2022-2032, USD (Million)
7.3.1.UK and European Union
7.3.1.1. UK
7.3.1.1.1. Neuroendocrine Tumor Treatment Market: By Drug, 2022-2032, USD (Million)
7.3.1.2. Germany
7.3.1.2.1. Neuroendocrine Tumor Treatment Market: By Drug, 2022-2032, USD (Million)
7.3.1.3. Spain
7.3.1.3.1. Neuroendocrine Tumor Treatment Market: By Drug, 2022-2032, USD (Million)
7.3.1.4. Italy
7.3.1.4.1. Neuroendocrine Tumor Treatment Market: By Drug, 2022-2032, USD (Million)
7.3.1.5. France
7.3.1.5.1. Neuroendocrine Tumor Treatment Market: By Drug, 2022-2032, USD (Million)
7.3.1.6. Rest of Europe
7.3.1.6.1. Neuroendocrine Tumor Treatment Market: By Drug, 2022-2032, USD (Million)

8. Asia Pacific Neuroendocrine Tumor Treatment Market, 2022-2032, USD (Million)
8.1. Market Overview
8.2. Neuroendocrine Tumor Treatment Market: By Drug, 2022-2032, USD (Million)
8.3.Neuroendocrine Tumor Treatment Market: By Region, 2022-2032, USD (Million)
8.3.1.Asia Pacific
8.3.1.1. China
8.3.1.1.1. Neuroendocrine Tumor Treatment Market: By Drug, 2022-2032, USD (Million)
8.3.1.2. Japan
8.3.1.2.1. Neuroendocrine Tumor Treatment Market: By Drug, 2022-2032, USD (Million)
8.3.1.3. India
8.3.1.3.1. Neuroendocrine Tumor Treatment Market: By Drug, 2022-2032, USD (Million)
8.3.1.4. Australia
8.3.1.4.1. Neuroendocrine Tumor Treatment Market: By Drug, 2022-2032, USD (Million)
8.3.1.5. South Korea
8.3.1.5.1. Neuroendocrine Tumor Treatment Market: By Drug, 2022-2032, USD (Million)
8.3.1.6. Rest of Asia Pacific
8.3.1.6.1. Neuroendocrine Tumor Treatment Market: By Drug, 2022-2032, USD (Million)

9. Latin America Neuroendocrine Tumor Treatment Market, 2022-2032, USD (Million)
9.1. Market Overview
9.2. Neuroendocrine Tumor Treatment Market: By Drug, 2022-2032, USD (Million)
9.3.Neuroendocrine Tumor Treatment Market: By Region, 2022-2032, USD (Million)
9.3.1.Latin America
9.3.1.1. Brazil
9.3.1.1.1. Neuroendocrine Tumor Treatment Market: By Drug, 2022-2032, USD (Million)
9.3.1.2. Mexico
9.3.1.2.1. Neuroendocrine Tumor Treatment Market: By Drug, 2022-2032, USD (Million)
9.3.1.3. Rest of Latin America
9.3.1.3.1. Neuroendocrine Tumor Treatment Market: By Drug, 2022-2032, USD (Million)

10. Middle East and Africa Neuroendocrine Tumor Treatment Market, 2022-2032, USD (Million)
10.1. Market Overview
10.2. Neuroendocrine Tumor Treatment Market: By Drug, 2022-2032, USD (Million)
10.3.Neuroendocrine Tumor Treatment Market: By Region, 2022-2032, USD (Million)
10.3.1.Middle East and Africa
10.3.1.1. GCC
10.3.1.1.1. Neuroendocrine Tumor Treatment Market: By Drug, 2022-2032, USD (Million)
10.3.1.2. Africa
10.3.1.2.1. Neuroendocrine Tumor Treatment Market: By Drug, 2022-2032, USD (Million)
10.3.1.3. Rest of Middle East and Africa
10.3.1.3.1. Neuroendocrine Tumor Treatment Market: By Drug, 2022-2032, USD (Million)

11. Company Profile
11.1. Advanced Accelerator Applications
11.1.1. Company Overview
11.1.2. Financial Performance
11.1.3. Product Portfolio
11.1.4. Strategic Initiatives
11.2. Dauntless Pharmaceuticals, Inc.
11.2.1. Company Overview
11.2.2. Financial Performance
11.2.3. Product Portfolio
11.2.4. Strategic Initiatives
11.3. Exelixis, Inc.
11.3.1. Company Overview
11.3.2. Financial Performance
11.3.3. Product Portfolio
11.3.4. Strategic Initiatives
11.4. Hutchinson Medipharma Limited
11.4.1. Company Overview
11.4.2. Financial Performance
11.4.3. Product Portfolio
11.4.4. Strategic Initiatives
11.5. Ispen
11.5.1. Company Overview
11.5.2. Financial Performance
11.5.3. Product Portfolio
11.5.4. Strategic Initiatives
11.6. Novartis AG
11.6.1. Company Overview
11.6.2. Financial Performance
11.6.3. Product Portfolio
11.6.4. Strategic Initiatives
11.7. Progenics Pharmaceuticals, Inc.
11.7.1. Company Overview
11.7.2. Financial Performance
11.7.3. Product Portfolio
11.7.4. Strategic Initiatives
11.8. Tarveda Therapeutics
11.8.1. Company Overview
11.8.2. Financial Performance
11.8.3. Product Portfolio
11.8.4. Strategic Initiatives